(Q47790283)

English

Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice

scientific article published on 8 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

toll-like receptor

0 references

0 references

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

author name string

Keita Oma

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Jizi Zhao

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Hirokazu Ezoe

3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Yukihiro Akeda

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Kosuke Kataoka

7

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Kazunori Oishi

8

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

language of work or name

0 references

publication date

8 April 2009

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

27

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

24

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

3181-3188

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Mucosal adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Toll-like receptors as adjuvant receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Modulating vaccine responses with dendritic cells and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Nasal colonization with Streptococcus pneumoniae includes subpopulations of surface and invasive pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Dynamics of dendritic cell migration and the subsequent induction of protective immunity in the lung after repeated airway challenges by nontypeable Haemophilus influenzae outer membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Antibacterial and Protective Properties of Monoclonal Antibodies Reactive with Escherichia coli O111:B4 Lipopolysaccharide: Relation to Antibody Isotype and Complement-Fixing Activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Immunological commonalities and distinctions between airway and digestive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.055

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.03.055

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/19446189

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47790283&oldid=2171100019"